Phase III Comparative Study of High-Dose Cisplatin Versus a Combination of Paclitaxel and Cisplatin in Patients With Advanced Non–Small-Cell Lung Cancer

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials

1995 • 2,804 citations

Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials

1996 • 2,541 citations

A Confidence Interval for the Median Survival Time

1982 • 831 citations

Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer

2000 • 719 citations

Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study.

1998 • 577 citations

Average Partial Association in Three-Way Contingency Tables: A Review and Discussion of Alternative Tests

1978 • 476 citations

Phase II Study of Taxol in Patients With Untreated Advanced Non-Small-Cell Lung Cancer

1993 • 441 citations

Phase II Study of Taxol, Merbarone, and Piroxantrone in Stage IV Non-Small-Cell Lung Cancer: The Eastern Cooperative Oncology Group Results

1993 • 346 citations

Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.

1995 • 302 citations

Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.

1998 • 277 citations

Combining Dependent Tests with Incomplete Repeated Measurements

1985 • 190 citations

Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre.

1997 • 181 citations

Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer.

1995 • 161 citations

Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial.

1996 • 131 citations

Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. Lung Cancer Working Party, Belgium.

1989 • 128 citations

Phase I Trial, Including Pharmacokinetic and Pharmacodynamic Correlations, of Combination Paclitaxel and Carboplatin in Patients With Metastatic Non–Small-Cell Lung Cancer

1999 • 102 citations

Lung cancer: worldwide variation in occurrence and proportion attributable to tobacco use

1993 • 68 citations

Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer.

1996 • 60 citations

Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC)

1995 • 56 citations

Phase II randomized trial comparing high-dose cisplatin with moderate-dose cisplatin and carboplatin in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party.

1994 • 51 citations

Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer

1995 • 46 citations

Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras gene status and chemosensitivity.

1995 • 45 citations

One-hour paclitaxel plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicentre, phase II trial

1998 • 45 citations

Phase II study of patients with metastatic nonsmall cell carcinoma of the lung treated with paclitaxel by 3-hour infusion

1997 • 43 citations

A randomized study of cisplatin versus cisplatin plus vindesine for non-small cell lung carcinoma

1991 • 42 citations

Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer

1997 • 36 citations

Non-Small-Cell Lung Carcinoma

1995 • 34 citations

Phase II Study of 3-Hour Infusion of Paclitaxel in Patients with Previously Untreated Stage III and IV Non-Small Cell Lung Cancer

1997 • 34 citations

Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: A phase II study

1997 • 33 citations

Paclitaxel 3-hour infusion given alone and combined with carboplatin: Preliminary results of dose-escalation trials

1996 • 31 citations

Paclitaxel by 96-hour continuous infusion in combination with cisplatin: a phase I trial in patients with advanced lung cancer.

1997 • 29 citations

Future directions in the treatment of non-small cell lung cancer

1991 • 28 citations

Paclitaxel and cisplatin in patients with non-small cell lung cancer: results of a phase II trial.

1996 • 26 citations

Rationale for the treatment of non-small cell lung cancer

1993 • 15 citations

Treatment of advanced non-small cell lung cancer (NSCLC): The ‘Umbria’ cooperative study

1989 • 14 citations

Phase I/II dose finding study of paclitaxel and carboplatin in advanced non-small cell lung cancer

1999 • 14 citations

Phase II study of a one hour paclitaxel infusion in combination with carboplatin for advanced non-small cell lung cancer

1997 • 13 citations

Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.

1997 • 12 citations

Management (chemotherapy/best supportive care) of advanced-stage non-small cell lung cancer

1996 • 9 citations

1111 A phase II study of paclitaxel in patients with non-small cell lung cancer

1995 • 6 citations

1107 Paclitaxel single agent in the first-line treatment of advanced NSCLC

1995 • 2 citations